Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,450 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,542 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05479578 | Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 7 | Rashmi Verma, MDOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 3 | 496 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY |
| 13 |
| Dec 31, 2024 |
| clinicaltrials |
| NCT02807805 | Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | active not recruiting | Phase 2 | 37 | Mamta ParikhOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05547061 | A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | active not recruiting | Phase 1 / Phase 2 | 91 | Cellbion Co., Ltd.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03569241 | PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases(STORM) | active not recruiting | Phase 2 | 196 | University Hospital, GhentOTHER | 6 | Dec 9, 2024 | clinicaltrials |
| NCT01444820 | Hypofractionated, Dose Escalation Radiotherapy for High Risk Adenocarcinoma of the Prostate | active not recruiting | Phase 3 | 329 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT01583920 | Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer | active not recruiting | N/A | 60 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT02730338 | INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4)(INTERVAL) | active not recruiting | N/A | 866 | Movember FoundationOTHER | 6 | Nov 27, 2024 | clinicaltrials |
| NCT03891732 | MRI Prostate for Chinese Men Being Screened for Prostate Cancer | active not recruiting | — | 690 | Chinese University of Hong KongOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors(STELLAR-001) | active not recruiting | Phase 1 | 325 | ExelixisINDUSTRY | 10 | Nov 19, 2024 | clinicaltrials |
| NCT04879563 | Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project(ASCAPE) | active not recruiting | Phase 2 | 500 | Region Örebro CountyOTHER | 4 | Nov 19, 2024 | clinicaltrials |
| NCT01957436 | A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer(PEACE1) | active not recruiting | Phase 3 | 1,173 | UNICANCEROTHER | 7 | Nov 12, 2024 | clinicaltrials |
| NCT04430192 | Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy(LuTectomy) | active not recruiting | Phase 1 / Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT02899312 | PSMA PET/CT for Assessment of Recurrent Prostate Cancer | active not recruiting | — | 2,244 | British Columbia Cancer AgencyOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03230734 | Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer(RAPSON) | active not recruiting | Phase 2 | 70 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT04571840 | Prostate Imaging Using MRI +/- Contrast Enhancement(PRIME) | active not recruiting | N/A | 500 | University College, LondonOTHER | 15 | Sep 23, 2024 | clinicaltrials |
| NCT05361902 | A First Step Towards Ultra-hypofractionation for Unfavourable Intermediate and High-risk Prostate Cancer(UPRATE) | active not recruiting | N/A | 35 | Erasmus Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04295447 | Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy(ADAM) | active not recruiting | Phase 2 | 190 | Universität MünsterOTHER | 2 | Jun 20, 2024 | clinicaltrials |
| NCT05682742 | Clinical Investigation of the da Vinci Surgical System | active not recruiting | N/A | 53 | Intuitive SurgicalINDUSTRY | 1 | Jun 3, 2024 | clinicaltrials |
| NCT04340245 | Exploiting Risk-Based Risk Stratification in Early Prostate Cancer to Discriminate Progressors From Non-Progressors(RECONCILE) | active not recruiting | — | 60 | University College, LondonOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04029714 | Prostate Cancer Active Surveillance Trigger Trial (PCASTT-UK): Comparing Current Practice for Men With Prostate Cancer on Active Surveillance (AS) to an AS Protocol With Standardised Triggers for Transitioning to Curative Treatment | active not recruiting | N/A | 195 | Guy's and St Thomas' NHS Foundation TrustOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT04909294 | Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma(STEREO-RML) | active not recruiting | N/A | 68 | Centre Georges Francois LeclercOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT01584258 | Prostate Advances in Comparative Evidence(PACE) | active not recruiting | Phase 3 | 2,205 | Royal Marsden NHS Foundation TrustOTHER | 4 | Jan 19, 2024 | clinicaltrials |
| NCT06193993 | Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients | active not recruiting | Phase 1 | 10 | National University Hospital, SingaporeOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT03377881 | Prostate Cancer Detection Using the Stockholm3 Test and MR/Fusion Biopsies(STHLM3MR-2) | active not recruiting | N/A | 12,750 | Karolinska InstitutetOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT04222634 | Metastasis-directed Therapy in Castration-refractory Prostate Cancer(MEDCARE) | active not recruiting | N/A | 18 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT01739062 | The ProCaRis Study: Prostate Cancer Risk Assessment in General Practice(ProCaRis) | active not recruiting | N/A | 5,000 | University of AarhusOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT04045717 | Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0 | active not recruiting | Phase 2 | 124 | Universitaire Ziekenhuizen KU LeuvenOTHER | 2 | Dec 1, 2023 | clinicaltrials |
| NCT03241537 | COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer | active not recruiting | Phase 3 | 61 | Samsung Medical CenterOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT04299620 | Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy | active not recruiting | N/A | 86 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT02881242 | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | active not recruiting | Phase 2 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT03381105 | From PSA to Stockholm3: Study Part 1(PSA2STHLM3/1) | active not recruiting | — | 13,431 | Helse Stavanger HFOTHER_GOV | 1 | Apr 24, 2023 | clinicaltrials |
| NCT00268476 | Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy(STAMPEDE) | active not recruiting | Phase 2 / Phase 3 | 11,992 | Medical Research CouncilOTHER_GOV | 2 | Apr 18, 2023 | clinicaltrials |
| NCT04138914 | Phase II Trial of Focal Cryotherapy for Prostate Cancer | active not recruiting | N/A | 30 | Singapore General HospitalOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT00430183 | Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer | active not recruiting | Phase 3 | 788 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 9, 2023 | clinicaltrials |
| NCT02803086 | Longitudinal Evaluation of Intestinal, Haematological and Urinary Toxicity From Pelvic Irradiation for Prostate Cancer(IHU-WPRT-TOX) | active not recruiting | — | 700 | IRCCS San RaffaeleOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT00860652 | Radiotherapy - Adjuvant Versus Early Salvage(RAVES) | active not recruiting | N/A | 333 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Nov 18, 2022 | clinicaltrials |
| NCT02044172 | Prostate Testing for Cancer and Treatment(ProtecT) | active not recruiting | N/A | 82,849 | University of OxfordOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT03061539 | Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature | active not recruiting | Phase 2 | 380 | University College, LondonOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT01464216 | MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness(FuncProst) | active not recruiting | — | 120 | Oslo University HospitalOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02623933 | MRI Assisted Focal Boost With HDR Monotherapy for Prostate Cancer Patients(MARS) | active not recruiting | N/A | 60 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04024475 | Prostate Cancer Biobank | active not recruiting | — | 1,323 | Swiss Cancer InstituteOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT03585114 | Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers | active not recruiting | Phase 2 | 11 | Columbia UniversityOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT03824275 | 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer | active not recruiting | Phase 2 / Phase 3 | 129 | Columbia UniversityOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT03444844 | Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 60 | Five Eleven Pharma, Inc.INDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT02243033 | Phase II Laser Focal Therapy of Prostate Cancer(LITT or FLA) | active not recruiting | — | 1,000 | HALO DiagnosticsINDUSTRY | 1 | Mar 25, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jan 8, 2025source: clinicaltrials